|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
EGFR tyrosine kinase inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2015
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Tagrisso
|
|
gptkbp:certification
|
Category 1
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase III
targeted therapy
FLAURA
AUR A1
AUR A2
AUR A3
|
|
gptkbp:contraindication
|
hypersensitivity to osimertinib
|
|
gptkbp:date
|
February 2016
|
|
gptkbp:developed_by
|
gptkb:temple
|
|
gptkbp:dosage_form
|
gptkb:tablet
once daily
|
|
gptkbp:duration
|
until disease progression
|
|
gptkbp:effective_date
|
gptkb:2015
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
film-coated tablet
|
|
gptkbp:healthcare
|
November 13, 2015
accelerated approval
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
osimertinib
|
|
gptkbp:indication
|
first-line treatment for EGFR mutation-positive NSCLC
|
|
gptkbp:ingredients
|
C18 H21 N7 O3 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
avoid strong CY P3 A4 inducers
monitor for QT prolongation with other drugs
|
|
gptkbp:is_atype_of
|
L01 X E30
|
|
gptkbp:is_monitored_by
|
Liver function tests
QT interval
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:lifespan
|
48 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:population
|
adults
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
|
|
gptkbp:symbolism
|
approved
|
|
gptkbp:targets
|
EGFR mutations
|
|
gptkbp:traded_on
|
gptkb:Tagrisso
|
|
gptkbp:type_of
|
1421373-65-0
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:year_created
|
gptkb:2012
|
|
gptkbp:bfsParent
|
gptkb:Tagrisso
|
|
gptkbp:bfsLayer
|
4
|